drugset / Trial / NCT04133480
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).
Timeline
- Start
- 2020-10
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 10 mg/kg | Oral |